Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Analytical validation of NeXT Personal, an ultra-sensitive personalized circulating tumor DNA assay.

The paper reports analytical validation of NeXT Personal, a tumor-informed ctDNA assay that uses whole-genome sequencing to track up to about 1,800 somatic variants.

OncotargetPubMed 38484152DOI 10.18632/oncotarget.28565